Clinical trial · Observational
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Arterial Hypertension With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (ArteRIB)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- parp inhibitors
- description
- All patients treated at least with 1 PARPi
- interventionNames
- Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
Primary outcomes (1)
- measure
- hypertension reports related to PARPi.
- timeFrame
- From inception to 16 Feb, 2023
- description
- Identification of the hypertension adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction, * patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib, pamiparib, fluzoparib (none). Exclusion Criteria: -chronology not compatible between the PARPi and adverse event
References
Publications (0)
Data not yet available